Caroline Stubbs, PharmD (c), Thy Ton-Morrison PharmD (c), Omar Alkedeh PharmD (c), Jonathan Huynh PharmD (c), Nikhil A. Sangave, PharmD, BCACP

home / authors / caroline-stubbs-pharmd-c-thy-ton-morrison-pharmd-c-omar-alkedeh-pharmd-c-jonathan-huynh-pharmd-c-nikhil-a-sangave-pharmd-bcacp

Articles

Temelimab: A Novel Disease-Modifying Agent for Diabetes Management

Temelimab: A Novel Disease-Modifying Agent for Diabetes Management

Caroline Stubbs, PharmD (c), Thy Ton-Morrison PharmD (c), Omar Alkedeh PharmD (c), Jonathan Huynh PharmD (c), Nikhil A. Sangave, PharmD, BCACP
October 15th 2021

Temelimab is a recombinant humanized IgG4 monoclonal antibody that blocks the HERV-W protein, which is associated with the pathology of autoimmune disorders, such as multiple sclerosis and type 1 diabetes.

Read More

Latest Updated Articles

Sweden - March 23, 2015: McDonald's yellow and red logo advertising sign placed on a pole with against clear blue sky
Published: October 23rd 2024 | Updated: October 24th 2024
What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders
10 Pharmacy Quotes That Will Make You Rethink the Profession
Published: January 18th 2016 | Updated: October 18th 2024
10 Pharmacy Quotes That Will Make You Rethink the Profession
Gabapentin Differs From Pregabalin in Several Key Ways
Published: September 22nd 2015 | Updated: October 14th 2024
Gabapentin Differs From Pregabalin in Several Key Ways
The US Capitol building.
Published: August 30th 2024 | Updated: November 21st 2024
Congress Requests Corrections to Testimony From Three Largest Pharmacy Benefit Manager Executives Following FTC Report
In this photo illustration, the Centers for Medicare and Medicaid Services (CMS) logo is displayed on a smartphone screen.
Published: October 8th 2024 | Updated: November 21st 2024
What Drug Rates Are Reported in Price Transparency Data?
Image Credit: Syda Productions - stock.adobe.com
Published: October 7th 2024 | Updated: November 21st 2024
What Went Wrong: How Formularies, Contracts, and Rebates Created a Headwind for Biosimilars